These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38944461)

  • 1. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'.
    Rinella ME; Narro GEC; Krag A; Terrault N; Newsome PN
    Ann Hepatol; 2024; 29(4):101178. PubMed ID: 38944461
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    Hepatology; 2024 Feb; 79(2):E16-E17. PubMed ID: 38112434
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    J Hepatol; 2024 Jul; 81(1):e20-e21. PubMed ID: 38906627
    [No Abstract]   [Full Text] [Related]  

  • 4. From NAFLD to MASLD: Promise and pitfalls of a new definition.
    Cusi K; Younossi Z; Roden M
    J Hepatol; 2024 Jul; 81(1):e18-e19. PubMed ID: 38906626
    [No Abstract]   [Full Text] [Related]  

  • 5. From NAFLD to MASLD: Promise and pitfalls of a new definition.
    Cusi K; Younossi Z; Roden M
    Ann Hepatol; 2024; 29(4):101179. PubMed ID: 38944463
    [No Abstract]   [Full Text] [Related]  

  • 6. From NAFLD to MASLD: Promise and pitfalls of a new definition †.
    Cusi K; Younossi Z; Roden M
    Hepatology; 2024 Feb; 79(2):E13-E15. PubMed ID: 38112428
    [No Abstract]   [Full Text] [Related]  

  • 7. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.
    Rinella ME; Sookoian S
    J Lipid Res; 2024 Jan; 65(1):100485. PubMed ID: 38103785
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].
    Liu YX; Guo F; Niu LN; Zhang B; Dou J; Xu Q; Ning ZH; Wang XZ
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):346-353. PubMed ID: 38733190
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
    Boldys A; Buldak L
    World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Hansen CD; Lindvig KP; Grønbæk H; Gluud LL; Thiele M; Krag A
    Ugeskr Laeger; 2024 May; 186(19):. PubMed ID: 38808766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature.
    ; ; ; ; ; ; ;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1190-1196. PubMed ID: 38529849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.
    Chen L; Tao X; Zeng M; Mi Y; Xu L
    J Hepatol; 2024 Feb; 80(2):e64-e66. PubMed ID: 37714381
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Conceptual changes for clinicians, researchers and patients.
    Lin SZ; Chen YW; Fan JG
    J Dig Dis; 2020 Nov; 21(11):604-609. PubMed ID: 32975050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we use old NAFLD data under the new MASLD definition?
    Song SJ; Lai JC; Wong GL; Wong VW; Yip TC
    J Hepatol; 2024 Feb; 80(2):e54-e56. PubMed ID: 37541393
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2020; 14(4):695-696. PubMed ID: 32442920
    [No Abstract]   [Full Text] [Related]  

  • 18. From NAFLD to MASLD: When metabolic comorbidity matters.
    Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
    Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research.
    Hsu CL; Loomba R
    Nat Metab; 2024 Apr; 6(4):600-602. PubMed ID: 38383845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease?
    Softic S; Kahn CR
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):143. PubMed ID: 30507644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.